TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33570787
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm implants (Group 1)
Study: 36107590
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg/kg)
Study: 34535520
Drug: Non-opioid pain
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid pain medications
Study: 35764103
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) (Group B)
Study: 35484990
Drug: CDP‐choline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP‐choline (5 mg/kg in 0.1 mL/kg 0.9% saline, IV; n=9)
Study: 35484990
Drug: Vehicle (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (0.1 mL/kg sterile 0.9% saline, IV; n=8)
Study: 35803302
Drug: Ventilatory strategy
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory strategy to prevent atelectasis (VESPA) with endotracheal intubation, recruitment maneuver, FIO2 titration (< 100%), and PEEP of 8 to 10 cm H2O.
Study: 33629258
Drug: Propranolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta-adrenergic receptor antagonist)
Study: 36184697
Drug: Mepolizumab 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 24 mg
Study: 36184697
Drug: Reslizumab 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 0.8 mg/kg
Study: 32276071
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg alcohol intake
Study: 34934126
Drug: Insulin Resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Resistance (IR)
Study: 33788436
Drug: Acupuncture (lifting‐thrusting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (lifting‐thrusting reinforcing and uniform reducing‐reinforcing methods) applied to specific acupuncture points for 20 min once daily for 3 months.
Study: 33788436
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group taking Tripterygium Wilfordii Polyglycoside tablets (one tablet per time, 3 times a day) for 3 months.
Study: 33788436
Drug: Acupuncture group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture group vs Medication group
Study: 33213125
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 120 mg HA, 240 mg CS, and 300 mg K once a day for 4 weeks
Study: 33783257
Drug: Trauma‐Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma‐Focused Cognitive Behavioral Therapy (TF‐CBT)
Study: 34210340
Drug: Budesonide/glycopyrrolate/formoterol fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate (BGF) 320/18/9.6 μg
Study: 34210340
Drug: Glycopyrrolate/formoterol fumarate
Normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate/formoterol fumarate (GFF) 18/9.6 μg
Study: 36121651
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus chemotherapy (360 mg Q3W or 240 mg Q2W plus XELOX or FOLFOX)
Study: 32798723
Drug: Saline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline alone (1000 mL)
Study: 35915267
Drug: NARC-15 tablets
Normalized name: Immunoglobulin g4-kappa, anti-(homo sapienspcsk9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, narc1, narc-1, proprotein convertase 9, pc9)), humanized monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: NARC-15 tablets oxycodone-acetaminophen 5/325 mg (A-OXY)
Study: 34968756
Drug: Brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab 6 mg
Study: 34534172
Drug: Dexmedetomidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.5 ng/ml; n=40)
Study: 34534172
Drug: S-ketamine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.75 μg/ml; n=20)
Study: 38604213
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy
Study: 35364051
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection
Study: 37625518
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen
Study: 36093647
Drug: 100 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/L CS‐OL‐NPs
Study: 36093647
Drug: 5% glutaraldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glutaraldehyde solution (GA)
Study: 36093647
Drug: 1 mg/ml
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/ml chitosan (CS)
Study: 33051045
Drug: Anthocyanin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin supplementation (125 mg, three times a day)
Study: 35227790
Drug: Conventional 3-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 3-dimensional conformal radiation therapy (CR)
Study: 32354952
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose solution (0.8 ml/kg)
Study: 34216034
Drug: tDCS targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS targeting L-DLPFC and SM1 simultaneously
Study: 34836350
Drug: Fructose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (1 g/kg BM)
Study: 36014763
Drug: Sucralose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (0.2 g in 300 mL)
Study: 35488261
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy
Study: 39570583
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT)
Study: 32442136
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of smartphones and tablets
Study: 32442136
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of smartphones and tablets among caregivers
Study: 39769201
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments
Study: 35182213
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral TAPB with 40 ml of 0.375% ropivacaine
Study: 32502267
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg twice daily
Study: 36057884
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 600 mg daily for 8 weeks
Study: 36143215
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment (PST) for 8 weeks
Study: 34008842
Drug: 900 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 µg vitamin D3
Study: 34008842
Drug: 900 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 µg 25(OH)D3
Study: 37891616
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin
Study: 33719606
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections after ultrasound-guided percutaneous lavage (UGPL)
Study: 33640982
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg orally
Study: 32162448
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution
Study: 33370477
Drug: Third-party bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-party bone marrow–derived MSC infusion
Study: 35393305
Drug: Intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent fasting (daily time-restricted eating; consuming food for not more than 8 hours/day, fasting for at least 16 hours/day)
Study: 37811711
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants
Study: 32538010
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at lower-he acupoints and front-mu acupoints combined with Tongxieyaofang (TXYF), oral administration of TXYF three times a day, routine acupuncture once a day for four weeks.
Study: 32538010
Drug: TXYF, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXYF, oral administration of TXYF three times a day for four weeks.
Study: 32538010
Drug: Pinaverium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide, 50 mg, oral administration three times a day for four weeks.
Study: 36757536
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg
Study: 36255564
Drug: endoscopic +
Approvals — FDA: no, EMA: no, PMDA: no
Description: endoscopic + β‐blocker
Study: 33872051
Drug: Water vapor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water vapor therapy (Rezūm™)
Study: 35978446
Drug: Fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Prozac) for 9 months
Study: 34180118
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium concentration (HNa, 143 mEq/L)
Study: 34180118
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium concentration (LNa, 138 mEq/L)
Study: 36455284
Drug: Reduced injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced injection technique (5 injection sites)
Study: 36455284
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection technique (20 injection sites)
Study: 32865374
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg daily
Study: 33359791
Drug: mAb AR9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb AR9.6 alone or in combination with gemcitabine
Study: 34297496
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg abelacimab
Study: 34297496
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg abelacimab
Study: 34297496
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg abelacimab
Study: 33984185
Drug: Ceramide-dominant moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide-dominant moisturizing cream and cleanser
Study: 34866567
Drug: Standard-of-practice CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-practice CBT (CC)
Study: 33222296
Drug: 4-implants (4-I)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-implants (4-I)
Study: 33222296
Drug: 6-implants (6-I)
Normalized name: LEVONORGESTREL 36MG/CAP X 6 IMPLANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-implants (6-I)
Study: 36354206
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (2.0-3.0 mg/kg/h)
Study: 39038404
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia
Study: 33877728
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg/day for 12 weeks
Study: 37164465
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg once daily)
Study: 35296793
Drug: Intradialytic parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic parenteral nutrition (IDPN) for 3 months
Study: 35553187
Drug: ebselen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebselen (10 mg/kg i.p.)
Study: 35931132
Drug: Pentalong® 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentalong® 50mg (PETN) twice daily
Study: 33751203
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 20 mL of 0.25% bupivacaine
Study: 33751203
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block with 20 mL normal saline (Control)
Study: 32040781
Drug: Focal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal therapy for localized prostate cancer
Study: 34328675
Drug: Intervention designed
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention designed to reduce concerns during the antenatal anomaly screening process (specific details on dosage and duration are not available).
Study: 33216782
Drug: Inhalation with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation with 100 mg of 2% lidocaine and 1mg of budesonide
Study: 32388918
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg monotherapy
Study: 32388918
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg monotherapy
Study: 32388918
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg monotherapy
Study: 32388918
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Candesartan, Amlodipine, and Atorvastatin
Study: 39305459
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment
Study: 34886746
Drug: Castor oil
Normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castor oil (60 mL)
Study: 37967228
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia
Study: 34225753
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy (IL‐1 or IL‐6 inhibition)
Study: 34225753
Drug: Non-biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic therapy
Study: 36142938
Drug: 1 fingertip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 fingertip unit (FTU) of EMLA® with microneedle patch for 30 min before cannulation
Study: 36142938
Drug: 0.5 FTU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 FTU of EMLA® with microneedle patch for 30 min
Study: 39054763
Drug: Treatment-As-Usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-As-Usual (TAU)
Study: 35339396
Drug: Herbal formula
Normalized name: Osteo Bi-Flex Joint Health Herbal Formula With Turmeric Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formula of Foeniculum vulgare and Rosa damascena (10 g, two times a day for 4 weeks)
Study: 32934722
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy
Study: 32227501
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day dried Ziziphus vulgaris for 12 weeks
Study: 35799088
Drug: Quintile of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quintile of patients with highest average heparin concentration (≥ 4.0 mg⋅kg‐1)
Study: 32598470
Drug: Generic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic antidepressants (sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, bupropion)
Study: 35369705
Drug: Vupanorsen (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen (various doses)
Study: 34218802
Drug: Levofloxacin concomitant
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin concomitant regimen (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice per day for two weeks)
Study: 36472884
Drug: L-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine
Study: 34602338
Drug: Maternal voice
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal voice intervention (voice recordings of the mother reading a children's book played during heel stick procedure once daily for 3 consecutive days)
Study: 34320709
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACTx)
Study: 34320709
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment only (Control)
Study: 32723193
Drug: 350 mg dose
Normalized name: aminophylline 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg dose of herbal supplement (70:30 blend of Rhaponticum carthamoides extract and Rhodiola rosea extract)
Study: 32723193
Drug: 175 mg dose
Normalized name: theophylline 175 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg dose of herbal supplement plus 175 mg of maltodextrin
Study: 38805733
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (placebo)
Study: 36129733
Drug: Endocare (virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocare (virtual reality digital treatment)
Study: 38325988
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (MT) alone
Study: 32620104
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg)
Study: 34339370
Drug: STRAP (Style
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRAP (Style Transfer Augmentation)
Study: 36456021
Drug: Inulin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (20 g/day of powdered supplement dissolved in water)
Study: 32796410
Drug: Kyphosis exercise
Normalized name: Kyprolis
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Kyphosis exercise and posture training intervention (twice weekly for 3 months)
Study: 35339397
Drug: Homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medicine Natrum muriaticum LM2
Study: 36045877
Drug: IM progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM progesterone in oil (25 mg daily)
Study: 36045877
Drug: IM progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IM progesterone in oil (50 mg daily)
Study: 36045877
Drug: Progesterone suppository
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone suppository (400 mg daily)
Study: 36045877
Drug: Progesterone suppository
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone suppository (800 mg daily; 400 mg twice daily)
Study: 36045877
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone suppository groups
Study: 34664221
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (VD3) 4000 IU daily for 3 months
Study: 32770661
Drug: 75 grams
Normalized name: vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 grams of oral glucose + 6 grams of oral sodium chloride (NaCl) load
Study: 35916700
Drug: Full imi
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full imi intervention web application (treatment)
Study: 35485687
Drug: Oral tablets
Normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets of zinc sulfate twice a day for 3 months
Study: 32331091
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (56-84 mg twice-weekly for 4 weeks) + oral antidepressant (AD)
Study: 32331091
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (56-84 mg once-weekly or once-every-other-week) + oral antidepressant (AD)
Study: 38330980
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI)
Study: 35737923
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg daily
Study: 35916128
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 40 mg)
Study: 35916128
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 32 mg)
Study: 35042738
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for 26 weeks
Study: 34918951
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 26 weeks
Study: 32643358
Drug: QLB dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLB dexmedetomidine intravenous (QD IV)
Study: 32228330
Drug: 5-mg fast-release
Normalized name: BAYER Fast Release Extra Strength 500 MG Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg fast-release melatonin
Study: 35640529
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral THC
Study: 35996073
Drug: Neostigmine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.04 mg/kg) and atropine (0.02 mg/kg) intravenously
Study: 32838813
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of oral ondansetron following ED visit
Study: 32838813
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of oral ondansetron